SCHEMBL25824173

SCHEMBL25824173

COc1cc(C)nc2ccc(N3CCOCC3)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.57
MAPT P10636 5/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
POLB P06746 3/20 0.57
MAPK1 P28482 2/20 0.57
TSHR P16473 1/20 0.57
HSD17B10 Q99714 1/20 0.57
MEN1 O00255 4/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
RXFP1 Q9HBX9 1/20 0.54
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
NCF1 P14598 1/20 0.51
THRB P10828 2/20 0.50
HPGD P15428 2/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24010843 0.95 MAPT (0.53) KMT2AMAPTSMN1; SMN2POLBMAPK1
SCHEMBL24006170 0.88 MAPT (0.51) KMT2AMAPTSMN1; SMN2POLBMAPK1
SCHEMBL24009992 0.88 ALDH1A1 (0.50) KMT2AMAPTSMN1; SMN2POLBMAPK1
SCHEMBL25824152 0.88 ALDH1A1 (0.54) KMT2AMAPTPOLBMEN1ALDH1A1
SCHEMBL25826715 0.86 MAPT (0.52) KMT2AMAPTSMN1; SMN2POLBMAPK1
SCHEMBL23999730 0.84 KMT2A (0.43) KMT2AMAPTSMN1; SMN2POLBMAPK1
SCHEMBL29125285 0.83 MAPT (0.55) KMT2AMAPTSMN1; SMN2POLBMAPK1
SCHEMBL29125302 0.81 MAPT (0.48) KMT2AMAPTSMN1; SMN2POLBMAPK1
SCHEMBL26317987 0.81 MAPT (0.41) KMT2AMAPTSMN1; SMN2POLBMAPK1
SCHEMBL29125442 0.81 KMT2A (0.57) KMT2AMAPTSMN1; SMN2POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR KMT2A 3925/4885MAPT 3962/4885SMN1; SMN2 1945/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR KMT2A 3974/4885MAPT 3999/4885SMN1; SMN2 2070/4885
US-20230219927-A1 AKT3 MODULATORS AKT3, AKT2, PIK3CA KMT2A 4131/4885MAPT 3976/4885SMN1; SMN2 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.